Eli Lilly’s stock is recovering after releasing underwhelming obesity pill trial data. Orforglipron caused less weight loss and more side effects than expected, falling short of Novo Nordisk’s oral semaglutide efficacy. Despite this, analysts believe Lilly’s daily pill could compete in the weight loss drug market if approved.
The race for a convenient obesity pill continues as Pfizer scraps contenders and Novo Nordisk and Eli Lilly explore new oral drugs. Novo Nordisk CEO expresses confidence in the oral semaglutide’s efficacy and commitment to ensuring patient access. Analysts forecast Eli Lilly’s pill to capture a significant share of the weight loss drug market by 2030.
Comparing clinical trial results is challenging, but early data suggests Novo Nordisk’s oral semaglutide may cause greater weight loss than Eli Lilly’s orforglipron. While Lilly’s pill helped patients lose an average of 12.4% of their body weight, Novo Nordisk’s semaglutide resulted in up to 16.6% weight loss in some patients. Investors express concern over side effects and discontinuation rates in Eli Lilly’s trial of orforglipron. Around 10.3% of patients on the highest dose discontinued due to side effects, mainly gastrointestinal like nausea and vomiting. Comparatively, patients on Novo Nordisk’s oral semaglutide reported similar side effects. Food requirements may pose a challenge for some patients taking Novo Nordisk’s pill. The manufacturing process for oral semaglutide is expected to be expensive. Pricing for orforglipron may be based on its value and health-care savings. It is uncertain how Eli Lilly will price the drug. Commercialization strategies will play a key role in market competition. Other obesity pills in development fall short in comparison to orforglipron and oral semaglutide. Viking Therapeutics’ mid-stage trial results were disappointing, leading to a drop in stock value. The once-daily pill helped patients lose weight, but had a high discontinuation rate. Experts believe Eli Lilly’s pill is more promising based on data comparison. 1. The CDC reports an increase in COVID-19 cases among children, with over 72,000 new cases in the last week. Hospitalizations have also risen, with 1,900 children admitted for treatment. The surge is attributed to the highly contagious Delta variant and low vaccination rates among children.
2. In economic news, the US unemployment rate fell to 5.2% in August, with 235,000 new jobs added. This marks a steady improvement in the job market, although challenges remain in industries like hospitality and retail. The Federal Reserve is closely monitoring these developments for future policy decisions.
3. The UN climate report warns of irreversible damage to the planet if immediate action is not taken to reduce greenhouse gas emissions. The report highlights the urgency of cutting emissions by at least 45% by 2030 to limit global warming to 1.5 degrees Celsius. Failure to do so could lead to catastrophic climate events.
Read more at CNBC
1. Tesla’s CEO, Elon Musk, announced plans to open the company’s Supercharger network to other electric vehicles later this year.
2. The U.S. economy added 850,000 jobs in June, exceeding expectations, with the unemployment rate ticking up to 5.9%.
3. Amazon’s Prime Day sales reached $10.4 billion, up 45% from last year, with small and medium-sized businesses achieving $3.5 billion in sales.: Eli Lilly’s obesity pill will rival Novo Nordisk’s oral Wegovy drug